
Get exclusive money-saving offers and guides
Straight to your inbox
Updated
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Cochlear Limited is a medical devices business based in Australia. Cochlear shares (COH) are listed on the Australian Securities Exchange (ASX) and all prices are listed in Australian Dollars. Cochlear has a trailing 12-month revenue of around $1.3 billion..
Our top pick for
US stocks
Our top pick for
Cheap broker fees
Our top pick for
Long-term investing
52-week range | $154.6 - $251.8466 |
---|---|
50-day moving average | $195.5612 |
200-day moving average | $203.2912 |
Target price | $184.4 |
PE ratio | 47.5161 |
Dividend yield | $3.35 (0.94%) |
Earnings per share (TTM) | $5.294 |
Standard brokerage - Australian shares
Competitive broker fees on Australian and international shares
Important: Share trading carries risk of capital loss.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the close of A$223.95 on 2020-10-22
1 week (2021-01-14) | 18.20% |
---|---|
1 month (2020-12-24) | 16.64% |
3 months (2020-10-23) | -0.46% |
6 months (2020-07-24) | 15.46% |
1 year (2020-01-23) | -5.55% |
---|---|
2 years (2019-01-23) | 15.99% |
3 years (2018-01-23) | 35.54% |
5 years (2016-01-22) | 133.74% |
Valuing Cochlear stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Cochlear's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Cochlear's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 48x. In other words, Cochlear shares trade at around 48x recent earnings.
That's relatively high compared to, say, the P/E ratio for the ASX over the 12 months to December 2019 (32.14). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Cochlear's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $259.6 million (£0.0 million).
The EBITDA is a measure of a Cochlear's overall financial performance and is widely used to measure a its profitability.
Revenue TTM | $1.3 billion |
---|---|
Operating margin TTM | 16.76% |
Gross profit TTM | $964.7 million |
Return on assets TTM | 6.99% |
Return on equity TTM | -22.4% |
Profit margin | -18.05% |
Book value | 21.336 |
Market capitalisation | $12.9 billion |
TTM: trailing 12 months
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Cochlear.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 24.39
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Cochlear's overall score of 24.39 (as at 01/01/2019) is nothing to write home about – landing it in it in the 45th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Cochlear is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 3.73/100
Cochlear's environmental score of 3.73 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Cochlear is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 14.34/100
Cochlear's social score of 14.34 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Cochlear is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 10.32/100
Cochlear's governance score puts it squarely in the 2nd percentile of companies rated in the same sector. That could suggest that Cochlear is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Cochlear scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Cochlear has, for the most part, managed to keep its nose clean.
Cochlear Limited was last rated for ESG on: 2019-01-01.
Total ESG score | 24.39 |
---|---|
Total ESG percentile | 44.88 |
Environmental score | 3.73 |
Environmental score percentile | 2 |
Social score | 14.34 |
Social score percentile | 2 |
Governance score | 10.32 |
Governance score percentile | 2 |
Level of controversy | 2 |
We're not expecting Cochlear to pay a dividend over the next 12 months.
Over the last 12 months, Cochlear's shares have ranged in value from as little as $154.6 up to $251.8466. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while Cochlear's is 0.3182. This would suggest that Cochlear's shares are less volatile than average (for this exchange).
Cochlear Limited provides implantable hearing solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers cochlear implants, including Nucleus 7, Nucleus 6, Nucleus CP802, and Kanso sound processors; and Baha bone conduction implants, such as Baha attract system, Baha connect system, Baha softband, Baha soundarc, Baha 5 sound processor, and Baha sound processor. It also provides Cochlear true wireless accessories comprising mini microphones, phone clips, and TV streamers; Nucleus water-safe accessories; and training and development services. Cochlear Limited was founded in 1981 and is headquartered in Sydney, Australia.
From the best overall face moisturiser for dry skin to the best body moisturiser, hand moisturiser and tinted moisturiser for dry skin, these are the best 7 moisturisers for dry skin you can buy in Australia right now.
From the best RC plane for beginners to the top model for aerial photography, these are the six best RC planes in Australia right now.
Steps to owning and managing Vanguard Australian Fixed Interest Index ETF units.
Steps to owning and managing Vanguard Ethically Conscious Global Aggregate Bond Index (Hedged) ETF units.
Steps to owning and managing ETFS Morningstar Global Technology ETF units.
Steps to owning and managing BetaShares Global Quality Leaders (Currency Hedged) ETF units.
Steps to owning and managing ETFS ROBO Global Robotics and Automation ETF units.
Steps to owning and managing ETFS FANG+ ETF units.
Steps to owning and managing ETFS S&P Biotech ETF units.
Steps to owning and managing ETFS Reliance India Nifty 50 ETF units.